icon-folder.gif   Conference Reports for NATAP  
 
 
 
 
Treatment With Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks Achieves 90% SVR12 in Treatment-Naïve Genotype 1, 4, 5, and 6 HCV-Infected Patients: The NEUTRINO Study
 
 
  Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2
trial..........http://www.natap.org/2013/HCV/033113_02.htm
 
Eric Lawitz1, David Wyles2, Mitchell Davis3, Maribel Rodriguez-Torres4, K. Rajender Reddy5, Ira Jacobson6, Kris V. Kowdley7, Evguenia Svarovskaia8, Deyuan Jiang8, John McNally8, Diana M. Brainard8, William T. Symonds8, John G. McHutchison8, Lisa Nyberg9, Zobair Younossi10
 
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2University of California, San Diego, School of Medicine, La Jolla, CA, USA; 3DigestiveCARE-South Florida Center of Gastroenterology, Wellington, FL, USA; 4Fundacion de Investigacion, San Juan, Puerto Rico; 5University of Pennsylvania, Philadelphia, PA, USA; 6Weill Cornell Medical College, New York, NY, USA; 7Digestive Diseases Institute, Virginia Mason Medical Center, Seattle, WA, USA; 8Gilead Sciences, Inc., Foster City, CA; USA; 9Kaiser Permanente, San Diego, CA, USA; 10Inova Fairfax Hospital, Falls Church, VA, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif